Breathe Well Live Well
Conditions: Chronic Obstructive Pulmonary Disease; Asthma; Overlap Syndrome
Interventions: Drug: LABA + LAMA; Drug: ICS; Drug: LABA + LAMA + ICS; Drug: LABA + ICS; Drug: other
Sponsor: Katholieke Universiteit Leuven
Not yet recruiting – verified June 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Asthma discovery may lead to new therapeutic approach
Insight News Mayo Clinic researchers and collaborators have discovered a key cellular mechanism that contributes to bronchoconstriction and inflammation in asthma. Their studies may lead to a novel, effective asthma therapy for patients. The findings appear in the … |
View full post on asthma – Google News
 |
A pathophysiological approach for FeNO: A biomarker for asthma.
Allergol Immunopathol (Madr). 2015 Mar 18;
Authors: Ricciardolo FL, Sorbello V, Ciprandi G
Abstract
The present review is focused on literature concerning the relevance of fractional exhaled nitric oxide (FeNO) in clinical practice from a pathophysiological point of view. There is increasing evidence that asthma is a heterogeneous pathological condition characterised by different phenotypes/endotypes related to specific biomarkers, including FeNO, helpful to predict therapeutic response in selected asthmatic populations. Nowadays FeNO, a non-invasive biomarker, appears to be useful to foresee asthma developing, to recognise specific asthma phenotypes, like the eosinophilic, to ameliorate asthma diagnosis and management in selected populations and to predict standard corticosteroid and biologic therapy efficacy. In addition, FeNO assessment may also be useful in patients with allergic rhinitis in order to detect the potential involvement of eosinophilic bronchial inflammation in “case finding” subjects at risk of asthma diagnosis. Therefore, it is possible to hypothesise a future with an appropriate use of FeNO by physicians dealing with worrisome clinical issues in specific asthma phenotypes.
PMID: 25796309 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Medical Xpress |
Severe asthma: Gallopamil confirmed as a therapeutic approach
Medical Xpress A team of Inserm researchers from the Cardio-Thoracic Research Centre of Bordeaux (Inserm/University of Bordeaux and Bordeaux University Hospital) has demonstrated the clinical efficacy of gallopamil in 31 patients with severe asthma. This chronic … |
View full post on asthma – Google News
 |
Related Articles |
Identifying barriers to chronic disease reporting in Chicago Public Schools: a mixed-methods approach.
BMC Public Health. 2014 Dec 6;14(1):1250
Authors: Rivkina V, Tapke DE, Cardenas LD, Harvey-Gintoft B, Whyte SA, Gupta RS
Abstract
BACKGROUND: Chronic disease among school-aged children is a public health concern, particularly for asthma and food allergy. In Chicago Public Schools (CPS), rates of asthma and food allergy among students are underreported. The aim of this study was to determine the barriers to chronic disease reporting as experienced by CPS parents and school nurses.
METHODS: A mixed-methods approach included focus groups and key informant interviews with parents and school nurses, and a cross-sectional survey was completed by parents. Qualitative data analysis was performed and survey data were analyzed to determine the significant demographic and knowledge variables associated with successfully completing the reporting process.
RESULTS: The three main barriers identified were 1) a lack of parental process knowledge; 2) limited communication from schools; and 3) insufficient availability of school nurses. Parents were significantly more likely to successfully complete the reporting process if they knew about special accommodations for chronic diseases, understood the need for physician verification, and/or knew the school nurse.
CONCLUSIONS: These findings suggest that increasing parental knowledge of the reporting process will allow schools to better identify and manage their students’ chronic conditions. A parent-focused intervention informed by these results has been completed.
PMID: 25481628 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Laboratory Equipment |
Novel approach to treating asthma
R & D Magazine Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating … Neutralizing Trigger Can Fight Asthma |
View full post on asthma – Google News
|
Novel approach to treating asthma: Neutralize the trigger
EurekAlert (press release) Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating … |
View full post on asthma – Google News
|
Scientists report new approach to defeating asthma by targeting allergen
News-Medical.net Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating … |
View full post on asthma – Google News
| Related Articles |
CXCR4 Antagonism as a Therapeutic Approach to Prevent Acute Kidney Injury.
Am J Physiol Renal Physiol. 2014 Jul 30;
Authors: Zuk A, Gershenovich M, Ivanova Y, MacFarland RT, Fricker SP, Ledbetter SR
Abstract
We examined whether antagonism of the CXCR4 receptor ameliorates the loss of renal function following ischemia-reperfusion. CXCR4 is ubiquitously expressed on leukocytes, known mediators of renal injury, and on bone marrow hematopoietic stem cells (HSC). Plerixafor (AMD3100, Mozobil ) is a small molecule CXCR4 antagonist that mobilizes HSCs into the peripheral blood and also modulates the immune response in in vivo rodent models of asthma and rheumatoid arthritis. Treatment with plerixafor before and after ischemic clamping ameliorated kidney injury in a rat model of bilateral renal ischemia-reperfusion. Serum creatinine and blood urea nitrogen were significantly reduced 24 hours after reperfusion, as was tissue injury and cell death. Plerixafor prevented the renal increase in the pro-inflammatory chemokines CXCL1 and CXCL5 and the cytokine IL-6. Flow cytometry of kidney homogenates confirmed the presence of significantly fewer leukocytes with plerixafor treatment; additionally, myeloperoxidase activity was reduced. AMD3465, a monocyclam analogue of AMD3100, was likewise renoprotective. Four weeks post-reperfusion, long-term effects included diminished fibrosis, inflammation and ongoing renal injury. The mechanism by which CXCR4 inhibition ameliorates AKI is due to modulation of leukocyte infiltration and expression of pro-inflammatory chemokines/cytokines, rather than a HSC mediated effect. The data suggest that CXCR4 antagonism with plerixafor may be a potential option to prevent AKI.
PMID: 25080523 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
A Computational Physiology Approach to Personalized Treatment Models: The Beneficial Effects of Slow Breathing on the Human Cardiovascular System.
Am J Physiol Heart Circ Physiol. 2014 Jul 25;
Authors: Fonoberova M, Mezic I, Buckman JF, Fonoberov VA, Mezic A, Vaschillo E, Mun EY, Vaschillo B, Bates ME
Abstract
Heart rate variability biofeedback intervention involves slow breathing at a rate of ~6 breaths per min (resonance breathing) to maximize respiratory and baroreflex effects on heart period oscillations. This intervention has wide-ranging clinical benefits and is gaining empirical support as an adjunct therapy for biobehavioral disorders, including asthma and depression. Yet, little is known about the system-level cardiovascular changes that occur during resonance breathing or the extent to which individuals differ in cardiovascular benefit. This study used a computational physiology approach to dynamically model the human cardiovascular system at rest and during resonance breathing. Noninvasive measurements of heart period, beat-to-beat systolic and diastolic blood pressure, and respiration period were obtained from 24 healthy young men and women. A model with respiration as input was parameterized to better understand how the cardiovascular processes that control variability in heart period and blood pressure change from rest to resonance breathing. The cost function used in model calibration corresponded to the difference between the experimental data and model outputs. A good match was observed between the data and model outputs (heart period, blood pressure, and corresponding power spectral densities). Significant improvements in several modeled cardiovascular functions (e.g., blood flow to internal organs, sensitivity of the sympathetic component of the baroreflex, ventricular elastance) were observed during resonance breathing. Individual differences in the magnitude and nature of these dynamic responses suggest that computational physiology may be clinically useful for tailoring heart rate variability biofeedback interventions for the needs of individual patients.
PMID: 25063789 [PubMed – as supplied by publisher]
View full post on pubmed: asthma